Skip to content

Advancing Pharmaceutical Innovation: IRBM, Campus Bio-Medico University of Rome (UCBM), and Campus Bio-Medico University Polyclinic Foundation (FPUCBM) Establish Framework Agreement

Ilaria Di Lorenzo (IRBM) and Carlo Tosti (UCBM) sign 3 year framework agreement to advance pharmaceutical innovation

With a three-year duration, it will operate in the fields of oncology, biopharmaceuticals, neuroscience, musculoskeletal system, and infectious diseases.

Rome, March 28, 2024 – A three-year framework collaboration agreement has been signed between the Campus Bio-Medico University of Rome (UCBM), the Campus Bio-Medico University Polyclinic Foundation (FPUCBM), and IRBM, an important center for scientific and pharmaceutical research specializing in drug discovery, including the discovery of new drugs, biochemistry, and molecular biology in areas such as oncology, neurodegenerative diseases, and infectious diseases. The framework agreement will focus on the areas of research and development in pharmacology, oncology, neuroscience, musculoskeletal system, infectious diseases, and biopharmaceuticals.

Present at the signing for IRBM were President and CEO Ilaria Di Lorenzo and CEO Matteo Liguori; UCBM Rector Eugenio Guglielmelli and CEO and General Manager UCBM Andrea Rossi; for the Campus Bio-Medico University Polyclinic Foundation, President Carlo Tosti and CEO and General Manager Paolo Sormani. The signing took place in the presence of the leaders and the scientific and research managers of the three institutions.

The framework agreement, in particular, provides for the possibility of creating educational and research projects; research programs for the development of new therapies and new technologies including access to their respective laboratories; research programs for advancing scientific knowledge; participation of university teaching-research staff and IRBM staff in studies and research; a student exchange program including PhD candidates, graduates, researchers, or professors; the joint organization of seminars, conferences, or scientific symposia and initiatives of common interest; collaboration in initiatives to spread scientific culture.

“This important agreement,” explained UCBM and FPUCBM President Carlo Tosti, “aims to triangulate research collaborations focused on the development of innovative drugs. The model of the agreement is inspired by the idea of a collaboration hub among pharmaceutical research, the university, and the research and care center, where each, with their own skills, can contribute to the identification of new disease targets, their therapeutic validation, and the development of new drugs. The areas of focus for the collaboration will mainly be the therapeutic areas of oncology, with a particular interest in rare tumors including those of the musculoskeletal system, and neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis.”

“We are thrilled to start this collaboration,” stated IRBM President and CEO Ilaria Di Lorenzo – “This agreement marks the joint commitment in merging the skills and resources of academia, industry, and clinical practice to enhance translational research with the common goal of accelerating the discovery and development of new therapeutic solutions and innovative drugs. The synergy between UCBM’s academic experience and FPUCBM’s clinical practice, together with IRBM’s industrial competence in Drug Discovery, thus opens new perspectives in the treatment of complex diseases and in the development of new technologies in the field of oncology, neurodegenerative diseases, and beyond.”

Company delegates and scientific team unit heads gather for the signing of the 3 year agreement between IRBM and UCBM

About the Campus Bio-Medico University of Rome (UCBM)
The Campus Bio-Medico University of Rome promotes integrated structures of teaching, research, and healthcare, pursuing the ultimate goal of its activities as the well-being of the person. It offers 14 degree courses across three Faculties: Departmental Faculty of Medicine and Surgery, Departmental Faculty of Engineering, Departmental Faculty of Sciences and Technologies for Sustainable Development and One Health, with courses delivered in Italian and English. The research laboratories of the Campus Bio-Medico University of Rome are concentrated in a dedicated facility, the Advanced Research Hub (PRABB) inaugurated in 2008, which is flanked by the new Cu.Bo Teaching Building, the Cultural Box which, together with the trapezoid, offers students state-of-the-art classrooms and aggregation spaces. The Campus Bio-Medico University of Rome has always been the university of “Science for Man.”

About the Campus Bio-Medico University Polyclinic Foundation (FPUCBM)
The Campus Bio-Medico University Polyclinic is characterized by the synergistic exercise of healthcare, teaching, and research activities. It has 60 operational units that provide services under agreement with the National Health Service (NHS), friend rate, and privately. It has 348 beds and 18 operating rooms and is equipped for minimally invasive and robotic surgery. It includes outpatient services, day hospital, day surgery, an emergency department, and inpatient wards organized by intensity of care. It has a Hospice for palliative care, also provided in home care, and an Oncology Hub in the Prenestino district of Rome. The Campus Bio-Medico University Polyclinic is accredited by the Joint Commission International (JCI) as the first Academic Hospital in Lazio. The health, teaching, and research activities carried out within the facility meet over 300 globally recognized quality and safety standards.

About IRBM
IRBM is a global leader in drug discovery, boasting a unique model of conducting all research within a single site, enabling unprecedented agility and efficiency, from concept to candidate. This model facilitates rapid advancements while minimizing setbacks. With a history of contributing to the development of four approved drugs, IRBM leverages deep collaborations and decades of experience from leading global institutions. IRBM’s comprehensive internal capabilities help partners achieve key milestones and progress towards clinical readiness, positioning the company as one of the main players in promoting innovation in the pharmaceutical and biotechnological sector.

Campus Bio-Medico University of Rome (UCBM):
Campus Bio-Medico University Polyclinic Foundation (FPUCBM):




Back To Top